Related Experiment Video

Updated: Jun 22, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Novel therapeutics for patients with non-muscle-invasive bladder cancer

Robert S Svatek1, Ashish M Kamat, Colin P Dinney

  • 1The University of Texas MD Anderson Cancer Center, Division of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Expert Review of Anticancer Therapy
|June 6, 2009
PubMed

Insights

Novel treatments for non-muscle-invasive bladder cancer (NMIBC) are advancing. Effective clinical trials require careful patient risk stratification to tailor therapeutic goals for bladder cancer recurrence and progression.

Area of Science:

  • Oncology
  • Urology

Background:

  • Non-muscle-invasive bladder cancer (NMIBC) presents a heterogeneous group of tumors.
  • Recurrence and progression rates vary widely among NMIBC subtypes.
  • Current treatment strategies require refinement to address this heterogeneity.

Purpose of the Study:

  • To review novel therapeutic agents and treatment paradigms for NMIBC.
  • To emphasize the importance of risk stratification in clinical trial design for NMIBC.
  • To discuss the differing goals of novel therapeutics based on cancer risk.

Main Methods:

  • Review of clinical experience with emerging NMIBC therapeutics.
  • Discussion of alternative chemotherapeutics, including apaziquone, docetaxel, and gemcitabine.
  • Exploration of novel delivery systems, gene therapy, and photodynamic therapy.

Main Results:

  • Several novel agents are progressing through clinical trials for NMIBC.
  • The efficacy of new therapeutics is dependent on patient-specific recurrence and progression risks.
  • Alternative chemotherapies and novel treatment modalities show promise.

Conclusions:

  • Future clinical trials for NMIBC must incorporate robust risk stratification.
  • Appropriate comparison groups are essential for evaluating novel NMIBC therapies.
  • Tailoring treatment goals to individual patient risk profiles will optimize outcomes for bladder cancer.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...